Archive for the ‘Demenz/Atrophie’ Category


Freitag, 13. September 2019


Metachromatische Leukodystrophie(MLD)

Sonntag, 06. Mai 2018


antipsychotics for her agitated and restless behavior.

Cases presenting with cognitive impairment have been reported

The leukodystrophies are a set of rare, progressive diseases that affect the growth or maintenance of white matter (ie, myelin).[1] Most leukodystrophies are genetic disorders and are inherited in a recessive, dominant, or X-linked manner, depending on the type of disease. However, some leukodystrophies appear to be sporadic rather than inherited.

Many leukodystrophies have adult-onset variants.[2] These include MLD, adrenoleukodystrophy, and Krabbe disease, in addition to many other rare varieties. MLD is one of the most serious and rare inherited demyelination disorders and eventually progresses to a bed-bound, quadriplegic state, with loss of speech and comprehension.[3] A lysosomal storage disease, it is transmitted as an autosomal recessive trait and is characterized by demyelination of the white matter in the central nervous system and peripheral nerves

MLD is clinically heterogeneous with respect to the age of onset, effects on the peripheral and central nervous systems, and disease progression. It can manifest in the late infantile period, early juvenile period, late juvenile period, or adulthood.[1,6,7] It usually has its onset between ages 1 and 4 years. It is characterized in this age group by progressive motor regression with gait difficulties, in association with neurocognitive decline and reduced output of speech. However, seizures are rare. A variable degree of neuropathy may be present. One third of the affected children have optic atrophy. The course of the disease is rapid and the outcome fatal, with a mean survival of 3-4 years.


Mittwoch, 18. Januar 2017





Freitag, 25. September 2015

Vd.a. progressive supranukleäre  Parese, subjektiv orientierend Symptomfrei. (Symptombeginn oft mit 50-60 Jahren).

Neurologisches Konsilium folgt.

(Kolibri-Zeichen,Humming-bird sign,Mikeymous Zeichen,Atrophie)

Swallow Tail Sign Parkinson

Dienstag, 30. September 2014

The ‘Swallow Tail’ Appearance of the Healthy Nigrosome
– A New Accurate Test of Parkinson’s Disease: A Case-
Control and Retrospective Cross-Sectional MRI Study at






Neuro_ROI Auswert_Software:


The Swallow tail sign : Parkinson mit CMRT Diagnostizieren !!!
A. High resolution SWI MRI (3D gradient echo EPI, magnitude image)
B. Clinical high resolution 3D-T2*/SWI MRI (Philips ‘PRESTO’ sequence),
In the retrospective study, MR imaging was performed on the same scanner as above, also with a standard eight-channel head coil, using a standard clinical Phillips ‘Principles of Echo Shifting with a Train of Observations’ (PRESTO) sequence. PRESTO is a HR-T2*/SWI 3D multi-shot fast field echo – echo planar imaging sequence FFE-EPI. TR/TE 16.55/23.29, echo train length 1, Flip angle 10°, number of slices: 200, voxel size 0.43×0.43×0.75 mm3, SENSE factor 2, Scan duration: 2 minutes 36 seconds). The orientation of acquired axial slices was in alignment with the splenium and genu of corpus callosum in the sagittal plane.


M. Parkinson(Neuroimaging)

Sonntag, 10. August 2014


(Siehe auch CMRT neurodegenerative Erkrankungen)

The first step involves the confirmation of symptoms necessary to make a diagnosis of parkinsonism, which includes the presence of bradykinesia, defined as slow initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions, and the presence of either muscular rigidity, a 4-to 6-Hz rest tremor, or postural instability not caused by visual, vestibular, cerebellar, or proprioceptive dysfunction.

The second step involves the identification of criteria that would exclude a diagnosis of PD including history of repeated strokes with stepwise progression of parkinsonian features (suggestive of vascular parkinsonism); history of repeated head injury (suggestive of pugilistic parkinsonism) or definite encephalitis, oculogyric crises; neuroleptic treatment at onset of symptoms (suggestive of drug-induced parkinsonism [DIP]); more than 1 affected relative; sustained remission; strictly unilateral features after 3 years; supranuclear gaze palsy (suggestive of progressive supranuclear palsy [PSP]); cerebellar signs; early and severe autonomic involvement (suggestive of multiple system atrophy [MSA]); early and severe dementia with disturbances of memory (suggestive of dementia with Lewy bodies [DLB]), language, and praxis (suggestive of corticobasal ganglionic degeneration); Babinski sign; presence of cerebral tumor or communicating hydrocephalus on CT scan; negative response to large doses of levodopa (if malabsorption excluded); and exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Finally, the third step is to identify at least 3 of the following supportive criteria for the diagnosis of PD: unilateral onset, rest tremor, progressive disorder, persistent asymmetry affecting side of onset most, excellent response (70%-100%) to levodopa, severe levodopa-induced chorea, levodopa response lasting at least 5 years, and a clinical course of at least 10 years.

Although PD is the most common cause of parkinsonism, multiple disorders include features of parkinsonism, which can make the differential diagnosis of PD a challenge (Table 1). The disorders most commonly confused with PD include essential tremor (ET), MSA, PSP, corticobasal degeneration (CBD), DLB, DIP, vascular parkinsonism, and psychogenic parkinsonism.

Essential Tremor

ET affects an estimated 10 million people in the United States and is one of the movement disorders most commonly confused with PD. ET can occur at any time throughout the lifespan; it is often associated with a strong autosomal dominant family history of tremor. In contrast to PD, ET involves the presence of postural and kinetic tremor with the absence of bradykinesia and rigidity. In addition, a reduction in tremor often occurs with ingestion of alcohol, tremor onset is typically bilateral, handwriting is large and tremulous, tremor often occurs in the head and/or voice, and tremor is the predominant symptom

Multiple System Atrophy

MSA is a neurodegenerative movement disorder; approximately 80% of cases have a predominantly parkinsonian form (MSA-P) and 20% have a cerebellar form (MSA-C). Early in the disease course, MSA can be indistinguishable from PD. However, MSA generally progresses more quickly, presents in the early 50s, and has a shorter disease course than PD.[15,16] Early autonomic symptoms are common and include orthostatic hypotension, urinary incontinence, and erectile dysfunction. MSA typically does not have a good response to levodopa; however, early in the disease course, an initial response to levodopa may be observed, but it is rarely sustained(—> CMRT)

Progressive Supranuclear Palsy

PSP is a neurodegenerative form of parkinsonism. The presenting symptom of PSP is often postural instability with associated falls, which has been shown to be one of the strongest predictors of a PSP diagnosis.[19] Another strong predictor of this disorder is vertical supranuclear palsy with downward gaze abnormalities.[20] Early and often significant cognitive changes, apathy, and disinhibition, as well as speech and swallowing problems are common with PSP. The onset of PSP tends to be symmetric, usually with minimal to no rest tremor, gait may be wide-based and ataxic, the response to levodopa is poor, and PSP generally progresses more quickly than PD. Rigidity tends to be greater in the neck than the limbs and it is not uncommon to see an extended posturing of the neck(—> CMRT)

Corticobasal Degeneration

CBD is one of the least common neurodegenerative forms of parkinsonism. It is a slowly progressive, asymmetric disorder with the core features of rigidity and apraxia, and a poor response to levodopa.[22] Varying degrees of cognitive dysfunction may also be present.(—> CMRT)

Dementia with Lewy Bodies

DLB accounts for up to 20% of all cases of dementia and can be difficult to differentiate from PDD and from AD.[24] The most common features are hallucinations, parkinsonism, and fluctuating attention. The diagnosis is generally DLB if dementia and parkinsonism occur within 1 year of each other, PDD if dementia occurs more than 1 year after parkinsonism, and AD when significant dementia occurs early with minimal to no parkinsonism at presentation.[25,26] In addition, parkinsonism is generally symmetric, whereas early gait and balance issues are common in DLB. Dementia primarily involves executive and visuospatial function in both DLB and PD, but it generally occurs early in DLB and late in PD. By contrast, early and severe memory impairment is seen in AD.[26] In addition, autonomic dysfunction may be present early in DLB, occurs much later in PD, and is rare in AD. Visual hallucinations are most common in PDD, less common in PD, and least common in AD. Finally, PDD has a strong response to levodopa, DLB has a less consistent response to levodopa, and AD has no response to levodopa(—> CMRT)

Drug-Induced Parkinsonism

DIP is the most common cause of secondary parkinsonism and generally results from the use of neuroleptics, antiemetics, and other dopamine blocking drugs. Its onset is generally acute, bilateral, and symmetric. Bradykinesia is the most common feature but rigidity, tremor, and gait abnormalities may also be present. DIP also tends to occur more often and to be more severe in older persons. In most cases, DIP is reversible and resolves within weeks to months after the offending agent is discontinued. The first step in the diagnostic process is to review the medication history and discontinue any potential causes of DIP

Vascular Parkinsonism

No specific diagnostic criteria have been formulated for vascular parkinsonism. However, studies have been conducted to identify key features and risk factors.[28] Cerebrovascular disease and risk factors have been shown to be significant features for differentiating vascular parkinsonism from PD. In addition, when compared with PD patients, those with vascular parkinsonism tend to be older, more often present with gait difficulty, often have predominantly lower body symptoms with postural instability and falling, and are more likely to have dementia, incontinence, and pseudobulbar affect. Bradykinesia and rigidity are common, but tremor is generally not present. Onset is typically sudden with stepwise progression. In addition, vascular parkinsonism usually responds poorly to levodopa.(—> CMRT)

Psychogenic Parkinsonism

Psychogenic parkinsonism is relatively rare compared with other psychogenic movement disorders but can at times be difficult to differentiate from PD.[29] No specific guidelines have been developed for the diagnosis of psychogenic parkinsonism. Key features include the resolution of symptoms with distraction or use of a placebo medication, task, or test. In addition, tremor generally has variable frequency and amplitude that tends to take on the frequency of other movements.


SPECT of patients with early PD shows an asymmetric reduction in dopamine transporter density that is greatest in the putamen, mild to normal in the caudate, and greatest contralateral to the most affected side of the body. In several studies, SPECT successfully differentiated PD/parkinsonism from ET with a sensitivity ranging from 87%-98% and a specificity ranging from 80%-100%. In these cases, the majority of the patients with PD had a reduction in dopamine transporter (DAT) density whereas the SPECT images for ET and control subjects were normal.

The Parkinson plus syndromes, MSA, PSP, CBD, and DLB, cannot be reliably differentiated from PD with SPECT because all have putamenal DAT reduction; however, it has been suggested that the caudate and putamen are more equally affected in the Parkinson plus syndromes and putamenal DAT exhibits a more symmetric reduction.[49,50] SPECT can however, be useful in differentiating DLB from AD, as DLB has a reduction in putamenal DAT whereas SPECT in AD is normal.[51,52] Studies have shown that SPECT can successfully differentiate DLB and AD with a sensitivity of up to 78% and specificity of up to 94%.

Positron Emission Tomography

PET is also a functional imaging technique and has higher resolution compared with SPECT; however, PET is more costly and is not widely available. A radioactive isotope, commonly 18fluorine or 11carbon, is attached to a compound, commonly DOPA or deoxyglucose, such that the binding and metabolism of the compound can be measured.[34] 18fluorine-DOPA is a marker of the striatal presynaptic dopaminergic terminal DOPA decarboxylase activity and can differentiate PD and other forms of degenerative parkinsonism from controls because parkinsonian patients have significantly less putamenal uptake. In addition, asymmetry is seen in patients with PD but not controls; the uptake in the caudate and putamen is about equal in controls, but patients with PD have an approximate 50% reduction in the putamen and a 10% reduction in the caudate.[55]

As with SPECT imaging, differentiation of various forms of parkinsonism is not reliable.

Transcranial Sonography

Multiple studies have shown a hyperechogenicity of the substantia nigra in up to 90% of patients with PD regardless of disease severity.[70-71] However, increased echogenicity is also seen in the substantia nigra of patients with DLB, CBD, and 9% of normal controls. The sensitivity of identifying PD was 48%-100% across 31 studies.

The limitations of this technique include the inability to complete the testing if the bone window is insufficient, potential variability of outcomes based on the equipment used and the interpreter, and currently limited follow-up and small sample sizes in the majority of the reported studies. The advantages of this technique are that it is less costly than other imaging techniques, and it is widely available, fast, easy to administer, and mobile. Further research is necessary to confirm the clinical utility of this technique in the differential diagnosis of PD.


The differential diagnosis of PD can be challenging and often cannot be determined based on clinical features alone. According to several diagnostic guidelines,[9-11] various neuroimaging techniques can be useful in the diagnosis of difficult cases in combination with published diagnostic criteria and the clinical judgment of a movement disorder specialist. At this time, SPECT imaging is most useful in differentiating PD from ET and nondegenerative forms of parkinsonism including psychogenic, drug-induced, and vascular parkinsonism, and for differentiating DLB and PD dementia from AD. MRI can rule out structural or ischemic lesions and can be useful in identifying vascular parkinsonism. There is also some evidence that MRI can differentiate between PD and MSA and also among the various Parkinson plus syndromes, based on the degree and distribution of atrophy. At this time, there is not enough evidence to recommend advanced MRI techniques, PET, or TCS in the differential diagnosis of parkinsonism, although each is promising; further study will determine their utility in diagnosing PD and related disorders



Montag, 25. November 2013





Samstag, 26. November 2011

Wähle: LEBERTUMORE _ Pankreastumore_ oder Neurodegenerative Erkrankungen Demenz



PCA Gefäßinfiltration, Pankreasgangstenose
PCA Gefäßinfiltration, Pankreasgangstenose
PCA Gefäßinfiltration, Pankreasgangstenose
PCA Gefäßinfiltration, Pankreasgangstenose


PSP Kolibrizeichen Hummingbird Sign
Olivopontocerebellare Atrophie(MSA-C)
Olivopontocerebellare Atrophie(MSA-C)

Persistierende A. trigemini



Alzheimer/Demenz Therapie

Samstag, 15. Oktober 2011

Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD)

Reaktion unter Therapie B), A) vor und C) nach Therapie :


Therapie der AD (prodromales Stadium bis schwere Demenz):

Die drei Cholinesterase-Hemmstoffe Donepezil, Galantamin und Rivastigmin sind bei Patienten mit leichter bis mittelschwerer AD zugelassen.

Die häufigsten Nebenwirkungen für alle Substanzen sind Übelkeit, Erbrechen und Durchfall, teils auch Benommenheit, Kopfschmerz, Gewichtsverlust und Muskelkrämpfe


Die Rivastigmin-Hochdosis-Pflaster-Therapie ermöglicht häufig eine Behandlung mit Vorteilen hinsichtlich der Konstanz der Wirkspiegel und der Compliance des Patienten.

Neue Studien zu Ginkgo biloba bei Alzheimer-Krankheit mit neuropsychiatrischen Symptomen geben Hinweise auf mögliche positive Effekte bei AD.

Es gibt weiterhin keine Studien zu einer verzögernden Wirkung auf die Konversion von einem „mild cognitive impairment“ (MCI) zur Demenz mit Acetylcholinesterase-Hemmern.

Acetylcholinesterase-Hemmer sind auch bei schwerer Demenz wirksam, aber gegenwärtig in Europa nicht zugelassen.

Memantin ist für die AD im mittleren und schweren Stadium (Mini-Mental-Status-Test [MMST]: 0–20 Punkte) zugelassen.

Eine Add-on-Behandlung mit Memantin bei Patienten, die Donepezil erhalten, ist der Monotherapie mit Donepezil bei schwerer AD

(MMST: 5–9 Punkte) überlegen. Eine Add-on-Behandlung kann erwogen werden. Jedoch nicht bei leichter oder mittelschwerer AD.


Memantin ist insgesamt gut verträglich. Eher seltene Nebenwirkungen sind Verwirrtheit, Schwindel, Kopfschmerzen und Obstipation.

Bei Niereninsuffizienz muss die Dosis reduziert werden. Regelmäßige Laborkontrollen sind nicht notwendig.


Therapie der anderen neurodegenerativen Demenzen (FTD, DLBD):

Frontotemporale Demenz mit Sonderformen (semantische Demenzen, primär progressive Aphasie):

Es gibt keine Evidenz für die Wirksamkeit der Acetylcholinesterase Hemmer bei den verschiedenen Formen der frontotemporalen Demenz (FTD).

Auch eine neue kontrollierte Studie mit Memantin war negativ.

Für motorische Unruhe und zwanghafte Verhaltensweisen wurden, zunächst auf der Grundlage von Fallberichten, Serotoninwiederaufnahmehemmer (SSRI) empfohlen.(Citalopram)

Das atypische Antidepressivum Trazodon zeigte in einer nichtkontrollierten Studie bei FTD-Patienten eine Reduktion von Reizbarkeit, Agitiertheit, depressiver Symptomatik und vermehrtem Appetit.

Als längerfristig einsetzbare „mood stabilizer“ sind im Einzelfall auch Valproat, Carbamazepin oder Lamotrigin zu erwägen.

Durch Mitbeteiligung des Striatums kann bei FTD ein begleitendes hypokinetisch-rigides Syndrom auftreten. In dieser Situation dürfen keine klassischen oder hochpotenten Neuroleptika gegeben werden, auch atypische Neuroleptika sollten nur mit Vorsicht angewendet werden.Bei Inkontinenz Versuch mit Trospiumchlorid.



Bei Demenz vom Lewy-Körper-Typ (DLBD) ist eine Wirksamkeit von Donepezil nachgewiesen, die Wirksamkeit von Donepezil, Rivastigmin und Memantin

bei gemischten Populationen von DLBD und Parkinson-Demenz konnte ebenfalls belegt werden.

Die Wirksamkeit von Memantin bei DLBD [20] ist noch unklar, es gibt erste Hinweise für eine eher ungünstige Wirkung bei dieser Erkrankung.


Eine Neuroleptikatherapie sollte zurückhaltend und nur bei klarer Indikation durchgeführt werden und, wenn unumgänglich, so kurz und niedrig dosiert wie möglich sein.

Eine besondere Herausforderung stellen die produktiv-psychotischen Symptome bei dieser Erkrankung dar. Psychotische Symptome können eine Reduktion der Parkinson-Medikation notwendig werden lassen.

Bei Lewy-Körper-Demenz und anderen Demenzen mit Parkinson-Syndrom ist die erhöhte neuroleptische Sensitivität zu beachten . Allerdings ist die Behandlung mit atypischen Neuroleptika oft nicht zu umgehen

und bietet im Vergleich mit typischen Neuroleptika auch ein vertretbares Risiko. Bei Fehlen von Studiendaten bevorzugen die Autoren der Cochrane Collaboration Quetiapin, das im Gegensatz zu Clozapin

weder die potenzielle Nebenwirkung der Agranulozytose hat noch anticholinerg wirkt.

Bei schwerer psychomotorischer Unruhe, die zu deutlicher Beeinträchtigung des Betroffenen und/oder der Pflegenden führt, kann ein zeitlich begrenzter Therapieversuch mit Risperidon empfohlen werden

(Empfehlungsgrad C, S3-Leitlinie DGN/ DGPPN 2009).Risperidon ist in der Behandlung agitierten und aggressiven Verhaltens bei Demenz wirksam.

.Es gibt Hinweise auf eine günstige Wirkung von Carbamazepin auf Agitation und Aggression.


Donnerstag, 12. Mai 2011
PSP Kolibrizeichen Hummingbird Sign
Olivopontocerebellare Atrophie(MSA-C)
Olivopontocerebellare Atrophie(MSA-C)


Bildinformation: i Anklicken !

Nur vorübergehend aus urheberrechtlichen Gründen zu Testzwecken zugänglich.

Zitiert aus der Radiologe u.a. . Work in progress.

Zur Demonstration einer Bildreferenzdatenbank.

Zur Werkzeugleiste springen